Form 4: Contineum Therapeutics Director, Sarah Boyce, Acquires Stock Options

Director Sarah Boyce acquired stock options in Contineum Therapeutics, Inc. on June 24, 2024.

Summary

• On June 24, 2024, Sarah Boyce, a director of Contineum Therapeutics, Inc. (CTNM), acquired 29,500 stock options.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program.
• The exercise price of the options is $19.19.
• One-third of the option shares vest and become exercisable on June 24, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to continuous service.
• Following the transaction, Boyce directly owns 29,500 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a common practice and generally viewed as a positive sign of alignment with shareholder interests.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options suggests a long-term commitment from the director to the company's success.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with those of shareholders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates